Recurrence of Uterine Adenomyosis After Administration of Gonadotropin-releasing Hormone Agonist and the Efficacy of Dienogest

This study elucidated the degree of adenomyosis recurrence following gonadotropin-releasing hormone agonist (GnRHa) discontinuation and dienogest efficiency for recurrent adenomyosis. This retrospective cohort study included 30 patients, divided into a group of patients whose progress was observed without providing additional therapy following GnRHa administration for six months (Group G) and a group of patients administered dienogest for six months following six months of GnRHa administration (Group D). Menorrhagia, dysmenorrhea, chronic pelvic pain, abdominal fullness, and uterine volume were recorded prior to treatment, six months after the start of therapy (6 M), and 12 months after the start of therapy (12 M). In Group G ( = 15), although all subjective symptoms disappeared at 6 M, nearly all symptoms recurred at 12 M. Uterine volume significantly decreased from 341.0 cm to 156.0 cm at 6 M ( = .001) and significantly increased again to 282.3 cm at 12 M ( = .003). In Group D ( = 15), all subjective symptoms disappeared at 6 M, and only abdominal fullness returned in a significant number of patients (5 of 5;  = .021) at 12 M. Uterine volume decreased significantly at 6 M ( = .003) and significantly increased again from 162.5 cm to 205.6 cm at 12 M ( = .006). Subjective symptoms, except for abdominal fullness, did not recur when dienogest was administered after GnRHa.